Back to discover
Drug

Iodine

In clinical development
Emerging researchLate-stage developmentRising momentum
Also known as Absorbine Veterinary Liniment, Barrier-Dyne, BovaPro, Bovadine+29 more

Absorbine Veterinary Liniment, Barrier-Dyne, BovaPro, Bovadine, ChoreMate One-Shot, Dairyland Brand Controlled Iodine Teat Dip, Defend II, Della Soft, Dermafive, EDX-1000, EDX-502, Eco-Gard, Eco-Plus, I2, Io-Blend, Io-Shield, Iodine Topical, Iodoshield, Jod, Lugols Strong Iodine, Optima Plus, Quarter Mate, QuarterMate Concentrate, Teat-Glo, Triumph, UdderBlend, Udderdine, West Dip, diiodine, iodo, jodum, molecular iodine, Iodip.

3
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Research2022-08-01Journal of the National Comprehensive Cancer Network : JNCCN

Reducing Microbial Levels in High Caries Risk Adults

Clinical trial2019-12-24Results posted · ClinicalTrials.gov

Nutrition and brain development in early life.

Research2014-03-28Nutrition reviews

Clinical Research Study Efficacy of a Prototype Oral Rinse

Clinical trial2009-12-01Results posted · ClinicalTrials.gov

Effect of Dietary Iodine Supplementation on the Proliferation of Breast Cancer

Clinical trial2009-12-01Primary completion · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Iodine
Aliases & brands
Absorbine Veterinary LinimentBarrier-DyneBovaProBovadineChoreMate One-ShotDairyland Brand Controlled Iodine Teat DipDefend IIDella SoftDermafiveEDX-1000EDX-502Eco-GardEco-PlusI2Io-BlendIo-ShieldIodine TopicalIodoshieldJodLugols Strong IodineOptima PlusQuarter MateQuarterMate ConcentrateTeat-GloTriumphUdderBlendUdderdineWest Dipdiiodineiodojodummolecular iodineIodip
RxNorm CUI
5933
ChEMBL ID
CHEMBL1201225
ATC codes
D08AG03
UNII
9679TC07X4

Clinical trials

6 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
6
registered trials across all phases
LATEST COMPLETION 2017
5
Late-stage (III+)
4
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 6
Phase 21Phase 32Phase 43

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20142022
Most influential

Nutrition and brain development in early life.

Nutrition reviews · 2014 · 638 cites

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 363 cites
Recent papers

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · 363 cites

Nutrition and brain development in early life.

Nutrition reviews · 2014 · 638 cites
Major research themes6
Adenocarcinoma1Gastrointestinal Microbiome1Iodine1Nutritional Status1Thyroid Carcinoma, Anaplastic1Thyroid Neoplasms1
Journals, researchers & institutions
Top journals
  • Journal of the National Comprehensive Cancer Network : JNCCN1
  • Nutrients1
  • Nutrition reviews1
Leading researchers
  • Amrein K1
  • Ball D1
  • Bernet V1
  • Bischoff L1
  • Blomain E1
  • Busaidy NL1
  • Campbell M1
  • Cassara CJ1
Leading institutions
free-text, unnormalised
  • Abramson Cancer Center at the University of Pennsylvania.1
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.1
  • City of Hope National Medical Center.1
  • Dana-Farber/Brigham and Women's Cancer Center.1
  • Duke Cancer Institute.1
  • Fox Chase Cancer Center.1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 6 of the same disease areas as Iodine in the shared literature.

6 shared diseases1 shared paper

Studied across 6 of the same disease areas as Iodine in the shared literature.

6 shared diseases1 shared paper

Studied across 6 of the same disease areas as Iodine in the shared literature.

6 shared diseases1 shared paper

Studied across the same disease area as Iodine in the shared literature.

1 shared disease1 shared paper

Studied across the same disease area as Iodine in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials